Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2021 | 1 |
2022 | 1 |
2023 | 1 |
2024 | 1 |
Search Results
2 results
Results by year
Filters applied: . Clear all
Quoted phrase not found in phrase index: "Grade 2 Rectal Obstruction, CTCAE"
Page 1
A phase I/II study of acute and late physician assessed and patient-reported morbidity following whole pelvic radiation in high-risk prostate cancer patients.
Acta Oncol. 2022 Feb;61(2):179-184. doi: 10.1080/0284186X.2021.1979246. Epub 2021 Sep 20.
Acta Oncol. 2022.
PMID: 34543143
Clinical Trial.
RESULTS: Median follow-up (FU) time was 4.6 years. No persistent late CTCAE grade 3+ morbidity was observed. Prevalence of CTCAE grade 2+ GI morbidities varied from 0 to 6% at baseline throughout FU time, except for diarrhea, which was re …
RESULTS: Median follow-up (FU) time was 4.6 years. No persistent late CTCAE grade 3+ morbidity was observed. Prevalence …
Timing of High-Dose-Rate Brachytherapy With External Beam Radiation Therapy in Patients With Intermediate- and High-Risk Localized Prostate Cancer and Its Effects on Toxicity and Quality of Life: A Randomized Controlled Trial (THEPCA).
Choudhury M, Thomas SS, Cain A, Palvai S, Nageshwaran S, Zhang J, Hayden K, Cain A, Hoskin P, Ahmed I.
Choudhury M, et al.
Int J Radiat Oncol Biol Phys. 2024 May 1;119(1):90-99. doi: 10.1016/j.ijrobp.2023.11.011. Epub 2023 Dec 30.
Int J Radiat Oncol Biol Phys. 2024.
PMID: 38163520
Clinical Trial.
METHODS AND MATERIALS: This was a single-center randomized trial in patients with intermediate- and high-risk localized prostate cancer who received HDR-BT before (Arm A) or after (Arm B) EBRT. Toxicities were graded using Common Terminology Criteria for Adverse Events ( …
METHODS AND MATERIALS: This was a single-center randomized trial in patients with intermediate- and high-risk localized prostate cancer who …
Item in Clipboard
Cite
Cite